Clinical trials: Attention Disorder
Mild, Moderate, or Severe Alzheimer's Disease
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
An open-label, exploratory, phase II, proof-of concept, clinical study to assess the safety and tolerability of EI-1071 and the effects of EI-1071 on neuroinflammation in patients with mild, moderate, or severe Alzheimer's disease
- Trial name
- NCT06745583
- Testing
- EI-1071 tablet, oral
- Where
- 2 sites in Taiwan
- Volunteers
- 7 people
- Sponsor
- Elixiron Immunotherapeutics Inc.
Attention Deficit Hyperactivity Disorder
Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD
The purpose of this protocol is to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy in Taiwanese children and adolescents with ADHD.
- Trial name
- NCT00485459
- Testing
- Atomoxetine Hydrochloride
- Where
- Taiwan
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Cognitive Impairment
Multi-Center Study of Sensory Stimulation to Improve Brain Function
The Overture Study is a randomized, controlled, single-blind multi-center clinical trial using the GammaSense Stimulation system to study safety, tolerability, and efficacy in people with mild to moderate cognitive impairment.
- Conditions
- Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia Alzheimers
- Trial name
- Overture (NCT03556280)
- Testing
- GammaSense Stimulation System (Active Settings)
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cognito Therapeutics, Inc.
Mild Cognitive Impairment
Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
Primary objective is to evaluate the neuroprotective effect of T-817MA on Tau protein phosphorylated at threonine 181 (p-tau 181) in cerebrospinal fluid (CSF) compared with placebo in patients with a diagnosis of MCI due to AD or…
- Trial name
- NCT04191486
- Testing
- T-817MA
- Where
- 37 sites in Czechia, Germany and 5 more
- Volunteers
- 221 people
- Sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
Attention Deficit Hyperactivity Disorder
A Study of Dex-methylphenidate Extended Release in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD)
This study compared the efficacy of dex-methylphenidate extended release 20 mg versus placebo during an 8-hour laboratory classroom day.
- Trial name
- NCT00564954
- Testing
- Dex-methylphenidate hydrochloride extended-release (Focalin XR)
- Where
- 5 sites in United States
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, Parkinson Disease
Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
Primary Objective: The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device.
- Conditions
- Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration
- Trial name
- MemorEM (NCT07222605)
- Testing
- MemorEM
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- eQ8Health Corporation d/b/a CareONE Concierge
Early Memory Loss, Mild Cognitive Impairment
NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)
This study will be an observational study in which patients who have been prescribed CerefolinNAC® are invited to participate in surveys regarding their experiences with CerefolinNAC®.
- Conditions
- Early Memory Loss, Mild Cognitive Impairment, Alzheimer's Disease, Vascular Dementia
- Trial name
- NCT01370954
- Testing
- CerefolinNAC®
- Where
- United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Pamlab, Inc.
Chorea, Huntington
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.
- Trial name
- NCT04400331
- Testing
- Valbenazine
- Where
- 34 sites in United States, Canada
- Volunteers
- 154 people
- Sponsor
- Neurocrine Biosciences
Huntington Disease, Tardive Dyskinesia
A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
This is a single-center, randomized, double-blinded, placebo-controlled, dose escalation trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy…
- Trial name
- NCT05238701
- Testing
- LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Huntington's Disease
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).
- Trial name
- NCT07536061
- Testing
- SRP-1005
- Where
- 5 sites in Australia, New Zealand and 2 more
- Volunteers
- 32 people
- Sponsor
- Sarepta Therapeutics, Inc.
Alzheimer's Disease
Improved Diagnosis of Alzheimer's Disease Using the Synchronous Neural Interaction™ Test
This study is designed to test the hypothesis that the Synchronous Neural Interaction™ Test is useful for diagnosing Probable Alzheimer's Disease according to standard criteria.
- Trial name
- NCT00666445
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Orasi Medical, Inc.
Attention Deficit Disorder With Hyperactivity
Efficacy and Safety of SPD465 in Adults With ADHD
The purpose of this study is to assess the safety and effectiveness of SPD465 compared to placebo (a capsule with no medication in it) in the treatment of ADHD.
- Trial name
- NCT00150579
- Testing
- Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate
- Volunteers
- 240 people
- Sponsor
- Shire
Chemotherapy-Related Cognitive Impairment, Healthy
Telerehabilitation Cognitive Impairments Following Chemotherapy Usability Study
Develop a game-based upper-extremity motor and cognitive rehabilitation system using custom and adaptable virtual reality simulations.
- Trial name
- TCIFCU (NCT04839588)
- Testing
- Usability study
- Where
- 2 sites in United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Bright Cloud International Corp
Aging, Mortality
Human Observatory Study
The Human Observatory Study is a prospective observational and ecological surveillance study building a continuously-updating world model for human health, disease, and death at the individual and population level.
- Conditions
- Aging, Mortality, All-cause Mortality, Life Expectancy
- Trial name
- HOS (NCT07646782)
- Testing
- Multi-Domain Ecological and Clinical Data Linkage
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Longevity Metrics, Inc.
Fragile X Syndrome, FXS
A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome
This is a single-center, randomized, double-blind, 2-period crossover study to explore the effects of BPN14770 on cognitive function and behavior in subjects with Fragile X Syndrome.
- Conditions
- Fragile X Syndrome, FXS, Fra(X) Syndrome
- Trial name
- NCT03569631
- Testing
- BPN14770
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Tetra Discovery Partners
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
- Trial name
- NCT02880956
- Testing
- ABBV-8E12
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 453 people
- Sponsor
- AbbVie
Huntington Disease
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Huntington disease (HD) is a hereditary neurodegenerative disorder causing impairment in movement, behavioral dysfunction and dementia.
- Trial name
- OPEN-HART (NCT01306929)
- Testing
- pridopidine
- Volunteers
- 134 people
- Sponsor
- Prilenia
MCI-AD, Early Stage Alzheimer's Disease, Alzheimer s Disease
Home-Based Closed-Loop Auditory Stimulation to Enhance Slow-Wave Activity in MCI Due to Alzheimer's Disease: A Proof-of-Concept Study
This proof-of-concept study explores whether long-term home-based closed-loop auditory stimulation during sleep enhances slow-wave activity (SWA) and yields preliminary efficacy signals in patients with amnestic mild cognitive…
- Conditions
- MCI-AD, Early Stage Alzheimer's Disease, Alzheimer s Disease, Mild Cognitive Impairment (MCI) Amnestic, AD
- Trial name
- Nana-Home (NCT07672977)
- Testing
- Closed-Loop Auditory Stimulation
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Bitbrain
Healthy Volunteers
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
The primary objective of this trial are to assess the pharmacokinetics (PK) of a single subcutaneous (SC) administration of teprotumumab high-concentration formula (HCF) in healthy adult non-Japanese and Japanese participants and…
- Trial name
- NCT06674941
- Testing
- Teprotumumab
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Amgen
Attention-Deficit Hyperactivity Disorder (ADHD)
PDC-1421 Treatment in Adult Patients With ADHD
Part II is a double-blind, randomized, parallel-group, placebo-controlled study. The primary objective of this trial is to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD.
- Trial name
- NCT05202327
- Testing
- PDC-1421 Capsule
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 99 people
- Sponsor
- BioLite, Inc.